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Background: In malaria endemic areas, schoolchildren usually have asymptomatic malaria infections and
consequently remain untreated. Therefore, intermittent preventive treatment with sulfadoxine-pyrimethamine in
schoolchildren would be a plausible strategy in malaria stable transmission areas to prevent anaemia and
malnutrition. However, in contrast to infancy and pregnancy, antimalaria intermittent preventive treatment in
children has been barely investigated. As the implementation of intermittent preventive treatment may be
challenged by sulfadoxine-pyrimethamine resistance, sulfadoxine-pyrimethamine combined with piperaquine may
be a better alternative than sulfadoxine-pyrimethamine monotherapy. A clinical trial is being conducted to assess
the efficacy and safety of intermittent preventive treatments versus controls in Democratic Republic of Congo
(DRCongo) schoolchildren and their impact on sulfadoxine-pyrimethamine resistance.
Methods/Design: A phase IIIb, randomised, controlled trial will enroll asymptomatic schoolchildren. For interventions,
sulfadoxine-pyrimethamine is compared to sulfadoxine-pyrimethamine plus piperaquine and to a control group. The
two treatments are given four-monthly from baseline for a year as a single dose for sulfadoxine-pyrimethamine and two
doses at 24-hour intervals for piperaquine. All participants receive praziquantel and albendazole as mass-treatment for
helminthiasis at enrolment. The primary endpoint is haemoglobin concentration change at 12 months follow-up.
Secondary endpoints are malaria parasite load and malaria prevalence, at baseline and at month 12. Malaria and
helminthiasis incidence will be monitored throughout the study. Statistical analysis will use multilevel modelling due to
repeated measurements and clustering effect of participants.
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Discussion: The very few studies on intermittent preventive treatment in schoolchildren in malaria stable
transmission areas have contradictory results. This randomised controlled trial is unique in comparing efficacy and
safety of a prophylactic combination therapy to monotherapy or a control group after 12 months follow-up.
Resistance markers for sulfadoxine-pyrimethamine (including break through parasitaemias) will also be recorded. Its
uniqueness lies also in the fact that we use piperaquine, a long acting antimalarial, in combination with sulfadoxine-
pyrimethamine. Artemisinin derivatives have been excluded as it is part of the treatment policies in virtually all
malaria endemic countries. Our findings may, therefore, contribute to the public health of youngsters who fail to
thrive and grow due to multiple morbidities.
Trial registration: NCT01722539; PACTR201211000449323
Keywords: Intermittent preventive treatment, Efficacy, Safety, Sulfadoxine-pyrimethamine resistance, Schoolchildren,
Malaria, Anaemia, Piperaquine, Randomised controlled trialBackground
Malaria is a major parasitic disease in developing countries
and particularly in Sub Saharan Africa (SSA). Malaria is
caused by five plasmodium parasites, the most severe being
Plasmodium falciparum [1]. More than half of the world
population is at risk for malaria. Globally, 243 million clin-
ical malaria cases and slightly more than 1 million deaths
are reported annually [2]; 90% of this burden occurs in
African children [3,4]. The Democratic Republic of Congo
(DRCongo) is likely one of the most affected countries.
The malaria transmission is perennial, malaria accounts for
86% of admissions in paediatric emergencies, and the inci-
dence in young Congolese children is estimated at 60 to
100 million malaria attacks per year [5].
Severe anaemia is one of the leading causes of death due
to malaria disease in childhood in intense and stable mal-
aria transmission areas [6]. In endemic areas where sub-
jects are permanently exposed to infectious mosquitos
bites, severe disease develops in infants and young chil-
dren. However, in children of five years of age and school-
age children, malaria infection is characterised by low
recurrent parasitaemia [7]. The prolonged carriage of
Plasmodium triggers the development of acquired immun-
ity, the premunition that somewhat protects older children
and adults against clinical malaria and reduces the risk of
death in school-age children [7,8]. Asymptomatic Plasmo-
dium infections, if untreated, persist and maintain malaria-
induced inflammation that is commonly associated with
iron deficiency anaemia through impaired intestinal iron
absorption and iron release from hepatocytes, and impair-
ment of the recycling of iron derived from parasitized red
blood cells phagocytosis [9]. In low income countries
(LICs), more than half of the school-aged population
suffers from anaemia; in SSA, approximately 85 million
school-aged children are affected. Anaemia reduces their
cognitive potential, retards their growth and predisposes
them to other diseases [6]. Also malaria accounts about for
13% to 50% of all annual school absenteeism and impairs
the educational achievement of children [10].Intermittent preventive treatment (IPT) with sulfadoxine-
pyrimethamine (SP) is a safe and efficacious control
tool for malaria that combined or not with insecticidal
treated nets, showed substantial protection against
malaria in vulnerable populations [11-13]. IPT treats
patients at long intervals, permitting drug concentra-
tions to fall below the minimal inhibitory concentra-
tion (MIC) between treatment courses. IPT is a public
health intervention that builds on clearing existing
parasites (treatment effect seen in mass drug admin-
istration) to avoid clinical malaria and prevent new
infections (prophylactic effect) without affecting the de-
velopment of immunity. Conversely, in chemoprophylaxis,
the blood concentration of the drug is maintained above
the level that inhibits the growth of (pre)erythrocytic
parasites [14].
IPT markedly reduces clinical malaria incidence and
overall child mortality, and improves haemoglobin concen-
tration and the nutritional status of children <5-years-old
[12,15]. Additionally, IPT may decrease malaria trans-
mission amongst the most vulnerable individuals through
a post-treatment prophylactic effect [14]. IPT is deliv-
ered through antenatal consultations for pregnant (IPTp)
women and through vaccination programs for infants
(IPTi). A policy recommendation has been developed
by the World Health Organization for IPTp and IPTi
[4,16,17]. Schools have been suggested as possible deliv-
ery sites for IPT in children (IPTc). Indeed, the education
sector may represent a reliable system for malaria con-
trol. IPT in schoolchildren (IPTsc) is likely the most feas-
ible and appropriate chemoprevention in stable and
endemic areas because schoolchildren are usually asymp-
tomatic to malaria infection and are consequently un-
treated in practice. Therefore, if proven effective, IPTsc
would be of direct benefit for the schoolchild, contribute to
malaria control at school, and facilitate on a community-
wide basis the implementation of other control interven-
tions, that is, vector control, IPTi, and malaria primary
diagnosis and treatment [18].
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half-life against efficacy, safety, tolerability and potential-
ity for cross-resistance selection [16]. Use of long-acting
drugs would result in fewer intakes and higher treatment
compliance. SP is an established product in the treat-
ment of IPTp. The drug has further proven safety and
tolerability in children in clinical trials. SP is slowly elim-
inated and provides 60-day antimalaria protection for
fully sensitive P. falciparum.
Other long-acting drugs available are mefloquine,
amodiaquine, and piperaquine. However, due to safety
concerns, mefloquine might not be optimal for IPT.
Amodiaquine is not suitable for IPT due to its three-
day treatment regimen and is used as a first line treat-
ment in several countries including DRCongo. Piperaquine
has been extensively used for mass prophylaxis and
treatment since 1978 in China and other malaria en-
demic countries of Asia [19]. Piperaquine has a long half-
live and may be a good IPT candidate in malaria endemic
countries [20].
Pyrimethamine binds to dihydrofolate reductase (DHFR)
enzyme and sulfadoxine to dihydropteroate synthase
(DHPS) and, thereby, the two SP components inhibit
the P. falciparum life cycle [21]. However, SP resist-
ance has spread globally due to pfDHFR and pfDHPS
gene mutations as a consequence of an increasing pro-
portion of individuals unnecessarily exposed to drugs
[22]. Of note, antimalarials with lengthy elimination
half-lives have a higher propensity of selecting for re-
sistance due to exposure of new infecting malaria para-
sites to the drug when its concentration tail falls below
the MIC [23].
To minimise the risk of SP resistance, SP could be
combined with piperaquine (SP-PQ) as recommended
by Cairns et al. and Gready [20,24]. Also, SP and SP-
PQ, given at four-month intervals in line with the
long half-lives (around 20 days) in paediatric patients,
may improve treatment compliance. Nevertheless, evi-
dence about the efficacy and safety of IPT SP and SP-PQ
in the presence of SP resistance strains selection is not
yet substantiated in schoolchildren. Only three clinical
trials with restricted treatment arms and/or follow-up
have so far been performed on IPTsc in hyper endemic
areas. Further clinical trials are warranted in other
settings. Through a randomised controlled trial (RCT)
we will assess the efficacy and safety of IPT SP or SP-
PQ regimens versus controls in schoolchildren of the
DRCongo.
Study hypothesis
Considering the facts that in our study area: (1) IPT of
malaria provides substantial protection against anaemia
and malaria in school children; (2) the level of SP resist-
ance has no significant impact on the prophylactic efficacy[25]; and (3) SP-PQ is safe and as efficacious as SP, we
hypothesize that antimalarial IPT with SP and SP-PQ
will improve haemoglobin concentration, reduce anaemia
prevalence, malaria incidence and parasitaemia, and im-
prove nutritional status and school performance in school-
aged children of DRCongo.
Methods/Design
Trial objectives and purpose
Primary objectives
This study primarily aims to assess the effect of antimal-
arial IPT on anaemia one year after initial intervention
in school-aged children of stable malaria transmission and
hyper endemic areas.
Secondary objectives
Secondarily, in the same study population, the purpose
of the study is to:
1. Determine the prevalence of SP resistance markers
at baseline and at month 12 follow-up;.
2. Compare the efficacy and safety of SP versus SP-PQ.
3. Assess the impact of antimalarial IPTsc on malaria
incidence and severity.
4. Evaluate the impact of IPTsc on the nutritional
status of schoolchildren.
5. Evaluate the effect of antimalarial IPTsc on school
performance.
6. Identify the potential environmental and host-related
predictors of malaria (re)infections.
Study design
Study area
The study is conducted in the Mokali health area of the
Biyela health zone, in Kinshasa province. The health
zone of Biyela has recently been identified as highly en-
demic for malaria and prevalent for schistosomiasis and
soil transmitted helminths (STH) (unpublished observa-
tions of Lutumba P). Biyela is urban–rural and its popu-
lation is estimated at 182,421 inhabitants. Biyela has
nine subzones of which two are considered rural. Three
rivers cross the health zone: Mango, Mabanga and
Mokali. Of the nine health areas of Biyela, Mokali is the
most populous with a population estimated at 27,455 in-
habitants. Biyela has one regional reference hospital that
is located in the Mokali health area. The participants in
the study are recruited at EP Boyambi and EP Likabo,
two of the nearest primary schools of Mokali to the re-
gional health centre. EP Boyambi and EP Likabo were
built by the Catholic Church and each school has 14
teachers and 12 classes (two classes per each school year).
The estimated number of schoolchildren was 650 per
school at the beginning of the year.
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Inclusion criteria for initial treatment
In order to be eligible, children should satisfy all of the
following criteria:
1. Male and female primary school children.
2. Anticipated local residence for the study duration.
3. Signed or thumb-printed informed consent by the
parents or guardians and witnessed by an impartial
witness (whenever parents/guardians are illiterate).
4. Informed consent for children 12-years-old or older.
Exclusion criteria
Participants with at least one of the following criteria are
excluded:
1. Children of the sixth primary school year.
2. Participation in any other investigational drug
study (antimalarial or others) during the previous
30 days.
3. Known or suspected hypersensitivity or serious
adverse events (AE) to the study drugs.
4. Malaria symptoms at baseline irrespective of the
severity [see Additional file 1].
5. Febrile conditions caused by diseases other than
malaria at the first visit.
6. Decompensated anaemia.
7. Illness or conditions, such as hematologic, cardiac,
renal, hepatic diseases, which in the judgement of
the investigators would place the subject at undue
risk or interfere with the results of the study,
including known glucose-6-phosphate
dehydrogenase deficiency and sickle cell.
8. Body weight <14 kg.
9. Children with major chronic infectious diseases
(HIV, tuberculosis, and so on).
Withdrawal criteria
Patients will be excluded from further assessment if any
of the following criteria are met:
1. Withdrawal of informed consent.
2. Severe AE related to the study drug.
3. Termination of the study prior to its planned end
date by the sponsor, regulatory authorities, or Ethics
Committee.
Every reasonable effort is made to complete a final
evaluation of participants who are withdrawn from the
study prior to the planned termination time period. The
study staff records the reason(s) for all withdrawals from
the study in the participants’ study records. At the time
of withdrawal, all study procedures outlined for the End
of Study visit should be completed. Any withdrawal orloss to follow-up are documented and notified to the site
coordinator as soon as possible.
Endpoints
Primary endpoint
The primary endpoint is the change in mean Hb con-
centration at month 12 of follow-up and anaemia preva-
lence one year after the initial preventive treatment.
Secondary endpoints:
1. Change in mean Hb concentration at month 4 and 8
of follow-up.
2. Prevalence of asymptomatic and clinical malaria at
baseline and one year after enrolment.
3. Prevalence of pfDHFR and pfDHPS gene mutations
at baseline and at month 12 follow-up.
4. Clinical (severe) malaria incidence and parasitaemia
at month 4, 8 and 12.
5. Percentages of acute and severe malnutrition at
month 0, 4, 8, 12 through weight/height and height/
age z-scores, and skin folds.
6. School achievement at the end of follow-up and
school attendance.
7. Prevalence and risk of environmental and host-related
predictors for malaria (re)infections.
Safety endpoints
Subjects are monitored throughout the study for pos-
sible development of AE. All AEs are recorded on the
specific form in the Case Report Form (CRF). Any changes
in relevant laboratory parameters are also assessed. For all
AEs, a relative risk (RR) and also the frequency, severity
and seriousness will be measured.
Design and sample size calculation
The study is an unblinded, randomised controlled trial,
enrolling asymptomatic school children, either gender.
At baseline, month four, and month eight, IPT with SP
or SP-PQ is given. SP is administered as a single treat-
ment dose. However, PQ is given as two doses with a
24-hour interval. IPT is administered at four month in-
tervals in line with the long half-lives of the drugs and
for compliance. Each treatment arm will be compared to
the control group of untreated participants. Due to the
prevalence of STH and schistosomiasis in the study area
all participants are treated with albendazole or prazi-
quantel according to the WHO guidelines [26]. Before
the study, parents or guardians and children were in-
formed about the objectives and the design of the study
during organised meetings at schools.
Within each school, each schoolchild is randomly
assigned to one of the two intervention groups or the
Table 1 Follow-up chart of study participants
Timeline in months Baseline 4 8 12
Informed consent X
Socio-economic and demographic X X
History (symptoms) X X X X
Examination (clinical) X X
Temperature X X X X
School achievement X X
Blood film X X X X
Hemoglobin (hemocontrol) X X X X
Thin and thick smear X X X X
Plasma sample X X
Filter paper PCR X X
Stool and urine sample X X
Malaria treatmentb X X X X
Anthelminthic treatment X Xa Xa X
Adverse events X X X X
Concomitant medications X X X X
aonly albendazole is given to participants. ball participants will receive SP at
Month 12 irrespective of the treatment allocation. In lines: we have the
timelines (in months) that are displayed as baseline, month 4, month 8 and
month 12. In columns are the study tasks that are performed and the
parameters that are collected. X means perform this task. Blank cells mean
that the specific activity will not be performed at the corresponding timeline.
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treatment. Each study arm consists of one-third of all
individuals.
To estimate the statistical power of our studies, we used
an effect size of 0.56 g/dl mean Hb level improvement by
the antimalarial IPT compared to the control treatment.
This effect size was based upon a previous study.
A previous study estimated the mean Hb concentra-
tion of 13.01 g/dl respectively in schoolchildren with
IPT and 12.45 g/dl without [27]. The sample size of the
study is all schoolchildren of two schools selected within
the nearest schools to the regional hospital centre. The
overall number of schoolchildren in the two schools is
estimated to be 1,300 (650 in each school). By excluding
200 children of the sixth primary school year (100 per
school), and accounting for 20% cancelation and 30% to
40% absenteeism, a realistic sample size of 616 individ-
uals is reached for the complete IPT treatment schedule.
Using this effect size and sample size, power estimates
were performed by Monte Carlo simulation. In each run,
a dataset was simulated assuming the within-subject
variance and between-subject variability was 16, and put-
ting in effect size to 1. The power was then estimated by
fitting a linear mixed model to the data (Hb level versus
treatment, time and time:treatment interaction) and test-
ing the significance of the interaction term. The power
is then equal to the fraction of times the interaction
term was significant, using a significance level of 5%. A
sample size of 616 offers 100% power to detect superior-
ity between the control and the intervention groups. For
the non-inferiority of SP versus SP-PQ, this sample size
has over 91% power to detect a difference in effect less
than 0.27 g/dl (<50%).
Study procedures
Baseline, enrolment and treatment allocation
General information on each school regarding compos-
ition, water sources, sanitation, health services, and
current and previous treatments are collected by ques-
tionnaire. The social, economic and demographic pat-
terns are recorded, physical/clinical and complementary
examinations are performed, and study treatments and
possible co-medications are given according to the study
treatment allocation and the participant’s health status
(see Table 1).
Follow-up visits at month 4, 8, 12
Each study participant is followed up for 12 months. If,
during the follow up, a child experiences clinical malaria
or other illnesses, s/he is advised to attend the health
centre for a treatment according to the national guide-
lines. Children absent from school at the time of the
follow-up visit are seen on another day of the week
for treatment and collection of three blood drops forhemocontrol and microscopy. To minimize reporting and/
or recall bias, teachers in each class are encouraged to con-
tact the site investigator when a study participant is absent
or is sick (by mobile phone). Any child with a health prob-
lem is advised to consult doctors at the regional hospital of
Biyela that is the health centre chosen for the study. Par-
ents and guardians are advised to visit the health centre
immediately when a child is unwell at home.
Clinical malaria cases observed during school visits are
documented and referred to the Biyela regional hospital.
At the end of follow-up all participants will receive one
dose of SP, albendazole and praziquantel and will be pas-
sively monitored for three months [See Additional file 2].
Health centre visit
A child attending the health centre is examined and
treated in line with national guidelines. All relevant
medical records (history, physical and clinical examin-
ation, laboratory results, the diagnosis and the prognosis
made by the clinician and the treatment given) of the




Sulfadoxine–Pyrimethamine is an established drug used
for uncomplicated malaria in children and adults and for
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has been widely established in infants and children in
clinical trials. For the current study the Fansidar brand
of SP is used. Fansidar is supplied as scored tablets,
containing 500 mg sulfadoxine and 25 mg pyrimeth-
amine unit doses. Sulfadoxine and pyrimethamine are
folic acid antagonists. Sulfadoxine inhibits the activity of
dihydropteroate synthase whereas pyrimethamine in-
hibits dihydrofolate reductase. In vitro, sulfadoxine and
pyrimethamine are active against the asexual erythro-
cytic stages of P. falciparum. SP may also be effective
against strains of P. falciparum resistant to chloroquine.
Fansidar is approved and commercialised for the treat-
ment of uncomplicated malaria and the prevention of
malaria.
Owing to its slow elimination profile, levels of SP suffi-
cient to inhibit parasite growth persist for 60 days after
treatment, providing a period of post-treatment prophy-
laxis during which successful development of a blood-
stage infection is prevented. After administration of one
tablet, peak plasma levels for pyrimethamine (approxi-
mately 0.2 mg/L) and for sulfadoxine (approximately
60 mg/L) are reached after about four hours. The vol-
ume of distribution for sulfadoxine and pyrimethamine
is 0.14 L/kg and 2.3 L/kg, respectively. Plasma protein
binding is about 90% for both pyrimethamine and
sulfadoxine. A relatively long elimination half-life is char-
acteristic of both components. The mean values for plasma
elimination half-lives are up to 11 days for sulfadoxine and
5 days for pyrimethamine, mainly via the kidneys [28].
Fansidar is given as a single oral dose of ½ tablet of
500 mg sulfadoxine - 25 mg pyrimethamine per 10 kg of
weigh: 1 tablet for weight less than 20 kg, 1.5 tablets for
20 to 29 kg, and 2 tablets for children who weigh 30 kg
or more.
Piperaquine
PQ is not approved as a single entity. A fixed dose combin-
ation of PQ with dihydroartemisinin (DHA) was approved
by the European Medicines Agency and marketed as
Eurartesim for the treatment of uncomplicated malaria in
children and infants of six months or older. The exact
mechanism of action of PQ is unknown. PQ likely mirrors
its closest structural analogue chloroquine. Chloroquine
binds to toxic haeme (derived from the patient’s haemoglo-
bin) within the parasite and prevents its detoxification. The
Cmax and the AUC0-24 of PQ is 179 nm/ml and 1.679
ng/ml*h, respectively. The elimination half-life of PQ is
around 20 days for paediatric patients. Due to its slow
elimination, PQ may accumulate in plasma after multiple
doses. In healthy volunteers, PQ exposure is increased ap-
proximately three-fold when administered with a high fat/
high calorie meal. In combination curative treatment with
DHA, PQ is safe and efficacious at 60 to 73.9 mg/kg dosein three daily doses against uncomplicated P. falciparum
malaria [29,30]. However, because participants in this trial
are healthy individuals, the parasite carriage is expected
to be low. Taking account of the ED90 of PQ at 1.68 ±
0.210 mg/kg/day for P. berghei K-173, its CT100 of 42
hours and the long elimination half-life [31], PQ 320 mg
tablets manufactured by Sigma Tau will be used at
two treatment doses of 16 to 24 mg/kg body weight
at 24-hour intervals (in combination with SP) as follows:
1 tablet for weigh 15 to 19 kg, 1.5 tablets for 20 to 29 kg,
2 tablets for 30 to 39 kg, and 2.5 tablets for 40 kg or




Albendazole is a benzimidazole anthelmintic agent highly
effective against a wide range of intestinal helminths
and, at higher doses, against tissue helminth infections.
Albendazole exhibits larvicidal, ovicidal and vermicidal
activity, and is thought to act via inhibition of tubulin
polymerization. This causes a cascade of metabolic dis-
ruption, including energy depletion, which immobilizes
and then kills the susceptible helminth. Albendazole is
poorly absorbed from the gastrointestinal tract due to its
low aqueous solubility. Oral bioavailability appears to be
enhanced when albendazole is co-administered with a
fatty meal (estimated fat content 40 g) as evidenced by
higher (up to five-fold on average) plasma concentrations
of albendazole sulfoxide as compared to the fasted state.
Plasma concentrations of albendazole sulfoxide increase
in a dose-proportional manner over the therapeutic dose
range following ingestion of a fatty meal (fat content
43.1 g). The mean apparent terminal elimination half-life
of albendazole sulfoxide typically ranges from 8 to 12 hours
in normal subjects. Albendazole sulfoxide is 70% bound to
plasma protein and is widely distributed throughout the
body. Following oral administration, albendazole has not
been detected in human urine. Biliary elimination presum-
ably accounts for a portion of the elimination [32].
Albendazole is used in children of 1 to 2 years at one
oral 200 mg dose and in adults and children older than
2 years at 400 mg in one oral dose. Albendazole will be
given at enrolment and four-month intervals in accord-
ance with the WHO guideline [26].
Praziquantel
Praziquantel is a trematodicide used for oral treatment
of infections due to schistosome and liver fluke. Prazi-
quantel induces a rapid contraction of schistosomes by a
specific effect on the permeability of the cell membrane.
The drug further causes vacuolization and disintegration
of the schistosome tegument. After oral administration
praziquantel is rapidly absorbed (80%), subjected to a
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neys. Maximal serum concentration is achieved one to
three hours after dosing. The half-life of praziquantel
in serum is 0.8 to 1.5 hours. However, in patients with
moderate-to-severe hepatic dysfunction (Child-Pugh class
B and C), praziquantel half-life, C max, and AUC increased
progressively with the degree of hepatic impairment. In pa-
tients with schistosomiasis the half-life is 2.99 hour ± 1.28,
the T max is 1.48 hour ± 0.74, the C max is 0.83 μg/mL ±
0.52 and the AUC is 3.02 μg/mL hour ± 0.59 (34). Prazi-
quantel will be given at 40 mg/kg at enrolment and at the
twelve-month follow-up [33].
Concomitant treatments
The administration of paracetamol (acetaminophen) is
allowed if the patient’s condition warrants it and should be
recorded in the appropriate section of the CRF. Drugs with
antimalarial activity (such as co-trimoxazole, macrolides,
tetracycline or doxycycline) should be reported as con-
comitant medications. All concomitant medications taken
by the patient during the study, from the date of signature
of the informed consent are recorded in the appropriate
section of the CRF.
Safety assessment
Safety and tolerability of the treatments are evaluated by
recording AEs and grading, laboratory, and vital signs
evaluations [34]. All AEs are recorded and classified in
accordance with their severity, seriousness, relationship
and outcome. The severity of a clinical AE is scored as:
mild when the patient is aware of the sign or symptom,
but it is easily tolerated; moderate when the discomfort
is enough to cause interference with usual activity; se-
vere when the event causes incapacity with inability
to work or perform usual activity; and life-threatening
when the patient is at risk of death at the time of the
event.
The investigators assess the drug-event relationship of
each AE/SAE by using clinical judgment. Alternative
causes, such as natural history of the underlying condi-
tions or diseases, concomitant therapy, other risk factors
and the temporal relationship of the event to the investi-
gational product are considered and investigated. The
investigator also consults the drug information and the
Data and Safety Monitoring Board as needed in the de-
termination of his/her assessment. For every AE, it is
very important that the investigator always make an as-
sessment of causality prior to transmission to the Trial
Management Group even if the investigator disposes of
minimal information to include in the initial report to
the Trial Management Group. The investigator may
change his/her opinion of causality in the light of follow-
up information, amending the SAE case report form
accordingly.The outcome of each AE must be assessed according
to the following classification: completely recovered, not
yet completely recovered, deterioration, permanent dam-
age, death, ongoing, or unknown.
All serious AEs, whether or not deemed drug-related,
or expected, must be reported immediately or within
24 hours (one working day), using the Serious Adverse
Event Notification Form by telefax or email to the spon-
sor. The report should state “Urgent Serious Adverse
Event” and highlight the study code on the cover page.
All other AEs not fulfilling the criteria of immediate
reporting are recorded on the Case Report Form. This
AE information is collected on a regular basis during the
clinical trial.
Statistical analysis plan
The effect of the type of intervention (either IPT versus
the controls, or SP versus SP-P) will all be analysed
using linear mixed model analysis. In each analysis, Hb
concentration is modeled versus time, testing whether
the change of Hb concentration over time differs be-
tween the two types of intervention. In each case, a linear
mixed model is fitted with Hb concentration as outcome
variable, and fixed effects including the type of interven-
tion (indicator variable), time and the interaction be-
tween them. In these models, the effect of interest is the
interaction between intervention and time, which for-
mally tests the null hypothesis that the change in Hb
concentration with time is the same in all interventions.
Significance of the interaction term is tested using the
F-test with a Kenwardroger correction for the number
of degrees of freedom. As the study includes several
(longitudinal) measurements within the same individ-
ual, and since the individuals cluster within schools, the
dependency between individuals will be accounted for by
including random effect terms into the model. More par-
ticularly, the model will include random effects (intercept
and slope) for individual, nested within the random effect
of school. An additional advantage of this technique is that
it gives unbiased results in case individuals are lost to
follow-up during the study.
Analysis of the data will be performed using the nlme
package from the statistical software R or the proc
mixed procedure from the software package SAS. All
statistical analyses will be performed in close collabor-
ation with StatUa, the Center for Statistics at the Univer-
sity of Antwerp.
Medicines accountability procedures
The study site maintains the study drugs under adequate
security. Study drugs sent to the study centre are verified
by the investigator or designee; the amount sent and the
exact supplies received are documented by signing and
dating the appropriate shipping documents. Study drugs
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tient who meets the enrolment criteria. The investigators
or designees record the patient’s number, patient’s ini-
tials and date dispensed on the Drug Accountability
Form. The investigators maintain an accurate running
accountability of the study drugs. At the end of the
study, final disposal of the unused drugs will be decided
by the sponsor after final reconciliation has been made.
Case report form
All data and observations are documented and entered
in the CRF. For this study, the CRF allows identification
of the study site and patient; recording of the selection
and inclusion of patients in the study; recording of all
data collected at each different study visit; recording of
possible AE and any suspension of the study. Partici-
pants are identified by their initials and a study identifi-
cation number on the CRF. When recording data on the
CRF and entering the data in the database, confidential-
ity and security of the forms are ensured at all steps. All
corrections are made on CRFs by striking through the
incorrect entry with a single line and entering the cor-
rect information adjacent to it. The correction is ini-
tialed and dated by the investigator. Additional records
are kept in the clinical and laboratory record books at
the core facility in Kinshasa. The investigators verify data
at each study visit.
Randomisation and treatment allocation
Children fulfilling the inclusion/exclusion criteria will
be assigned a sequential study number and will be
treated according to a predetermined randomization list
of blocks of varying size per school. Within each block
each schoolchild will randomly be assigned to one of the
two intervention groups or the control group in 1:1:1 bal-
ance. Sealed envelopes labeled with the school unique
code and containing the list with the treatment allocated
to the participants will be provided according to the
above mentioned list and opened at the moment the chil-
dren are recruited.
Treatment administration
The study treatment is administered under the direct
supervision of a study nurse. Study drugs are given to
the children consistent with the investigational brochure
of each product. After drug administration, children will
be kept for thirty minutes in the class. In case vomiting
occurs within 30 minutes of administration a dose is re-
peated in full. This event is documented in the CRF. If
vomiting persists beyond two additional doses, the child
is withdrawn from the study.
Upon arrival at a school, an inventory is performed
and a drug receipt log filled out and signed by the staff.
Accountability for the drug at all school sites is theresponsibility of the principal investigator. The investiga-
tors ensure that the drug is used only in accordance with
this protocol. Accountability records include dates, quan-
tities, lot numbers, expiration dates, and patient numbers.
Quality assurance
To ensure the rights, safety and well-being of the human
subjects enrolled in this trial and to validate the Investi-
gator’s adherence to the protocol, all applicable regula-
tions of the International Conference on Harmonisation
(ICH) and the Good Clinical Practices (GCP) guidelines
are strictly applied. The quality assurance of records and
data are guaranteed. The study clinicians are trained
about the study protocol prior to the onset of the trial.
The study clinicians complete case records at each hospital
visit. The medical records of the clinicians are transferred
to a CRF by the investigators. At school visits, the investi-
gators record data on the CRF. The investigators carry out
100% Source Data Verification on the data collected at the
regional hospital centre during the passive follow-up to
guarantee the best conduct of the study. To ensure accur-
acy of the data, a CRF completed by an investigator is
contra-checked by another investigator. The consistence of
data of each participant is checked by the investigators at
each follow-up visit by cross-checking the reports of the
school teachers and of parents/guardians, and the medical
records at the regional hospital centre. The investigators,
therefore, have frequent contacts with the clinicians and
the school teachers.
Data management
All data is processed from the CRF into an electronic
database by two different persons after each follow-up
visit. Then the two files are merged. Unmerging infor-
mation is verified and corrected and added to the final
database. During the conduct of the study, data are veri-
fied and reviewed to produce and maintain high quality
data. All unresolved issues are queried and resolved be-
fore locking the database. Data transfer and handling are
done with appropriate security measures and with regard
to rights, safety and well-being of trial subjects. Two
back-up files of the database are stored on compact discs
after each data entry session. For quality control, check
programs are written into the database to limit the entry
of incorrect data and ensure entry of data into required
fields.
Ethical considerations
The Investigators agreed to conduct the present study in
full agreement with the principles of the ‘Declaration
of Helsinki’ and subsequent relevant amendments. All
research activities will be conducted in accordance with
the standards and codes of conduct accepted by the
ICH guidelines. The study is approved by the Ethical
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of the School of Public Health, University of Kinshasa,
DRCongo. Approval was also obtained from the Ministry
of Health of DRCongo. Prior to the start of the project,
special permission was obtained from the DRCongo
Ministry of Education and the local health and education
authorities of Biyela. Written informed consent was
obtained from the guardians for all children before enter-
ing the study. An assent was obtained, as well, from chil-
dren who were 12-years-old or older. In the control arm
no treatment is given as no foreseeable serious risk can
be anticipated and no standard of care yet exists in
schoolchildren. All participants are followed-up, exam-
ined and treated free of charge if malaria or other ill-
nesses occur during the period of the study.
To measure Hb level and P. falciparum parasitaemia,
finger pricks are done at each visit for hemocontrol and
microscopy. A total of 3 ml of venous blood is collected
at baseline and month 12 for genotyping and other tests
that the clinician may request for the management of ill-
nesses. Residual plasma is separated, stored and trans-
ported at −70°C to be assayed by ELISA and fluorescence
activated cell sorting (FACS) for malarial cytokines and
antibody quantification and other malaria-related parame-
ters (described in an independent protocol after the oper-
ational part of the study is finished). The human genome
will not be examined.
Discussion
Little research has been performed on IPTsc in malaria
stable transmission. Rohner et al. [35] found no effect for
IPT with SP monotherapy given at baseline and three
months later to schoolchildren. On the other hand, Clarke
et al. [27] found a reduced prevalence of anaemia by 50%
for a ‘sulfadoxine-pyrimethamine plus amodiaquine’ IPT
combination therapy given three times at four-month in-
tervals at one year follow-up compared to a placebo. They
also reported a significant improvement from the IPT
intervention on the behavioural and educational achieve-
ments of the schoolchildren. Similarly, Nankabirwa et al.
[36] reported a decreased risk of malaria parasitaemia
following 42 days follow-up for dihydroartemisinin-
piperaquine (11.7% (95%CI:7.9 to 17.1)) and ‘amodiaquine
plus SP’ (44.3% (95%CI:37.6 to 51.5)) compared to a SP
monotherapy (79.7%(95% CI:73.6 to 85.2)), and to a pla-
cebo (84.6%(95% CI: 79.1 to 89.3)).
Our clinical trial is unique in investigating the im-
pact of antimalaria IPT in schoolchildren of hyper en-
demic areas for longer follow-up, resistance markers
for SP at baseline and after 12 months (including break
through parasitaemias). Our study is also unique in using
piperaquine in combination with SP. Artemisinin deriva-
tive has been excluded as it is part of the treatment policies
in virtually all malaria endemic countries [37].The findings of the clinical trial are, therefore, expected
to make a major contribution to the public health of





Written informed consent was obtained from the partic-
ipants’ parents or guardians for the conduct of the study
and the publication of this manuscript. As part of the
clinical trial protocol, an information sheet for partici-
pants and an informed consent form were reviewed and
approved by the Ethical Committee of the University of
Antwerp, Belgium, the Ethical Committee of the School
of Public Health, University of Kinshasa, DRCongo and
the Ministry of Health of DRCongo. A copy of the infor-
mation sheet and the written consent form in French,
English and in the local language are available for review
by the Editor-in-Chief of the Trials Journal.
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